Lumenis announced that the OptiLight has received the MedTech Breakthrough Award for “Best New Technology Solution for Ophthalmology.” The win follows Lumenis’ MedTech awards for “Best Overall Medical Device Company in 2021” and “Best New Surgical Technology Solution in 2020.”

OptiLight is the first and only light treatment FDA approved for management of dry eye disease. Lumenis’ patented, innovative Optimal Pulse Technology (OPT) offers targeted, uniform, precise, and controlled treatment that safely and effectively breaks the cycle of inflammation associated with dry eye disease.

“Dry eye disease is highly prevalent and difficult to manage, and traditional treatments like warm compresses and artificial tears treat the symptoms but not the underlying pathology,” said James Johnson, managing director, MedTech Breakthrough. “OptiLight is leading a revolution in managing dry eye disease with ‘breakthrough’ technology that allows doctors to treat patients quickly, in-office. With broad potential for tens of millions with dry eye disease, OptiLight stands out from the crowd to become our 2022 Best New Technology Solution for Ophthalmology.”

“We’re grateful to MedTech for honoring OptiLight for its innovation and impact in eye care,” said Lumenis CEO Tzipi Ozer-Armon. “Lumenis is committed to raising the bar for patients’ health by providing cutting-edge solutions and treatment innovations. As the only light-based treatment for dry eye disease, OptiLight has the power to elevate dry eye management and improve health and quality of life for millions of people around the world.”